Advanced Micro Devices Inc. logo

Advanced Micro Devices Inc. (AMD)

Market Closed
23 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS)
$
516. 79
+8.86
+1.7443%
$
843.65B Market Cap
1,401.5 P/E Ratio
- Div Yield
15.14M Volume
2.65 Eps
$ 507.93
Previous Close
Add Transaction
Day Range
508.36 523.92
Year Range
188.22 658.52
Want to track AMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Advanced Micro Devices (AMD) Ascends While Market Falls: Some Facts to Note

Advanced Micro Devices (AMD) Ascends While Market Falls: Some Facts to Note

Advanced Micro Devices (AMD) reachead $170.97 at the closing of the latest trading day, reflecting a +0.04% change compared to its last close.

Zacks | 2 years ago
What Wall Street Thinks of AMD Stock Ahead of Thursday's 'Advancing AI' Event

What Wall Street Thinks of AMD Stock Ahead of Thursday's 'Advancing AI' Event

Advanced Micro Devices (AMD) will hold its "Advancing AI" event this week, with analysts expecting new product announcements that could drive the stock higher and lift sales.

Investopedia | 2 years ago
Why AMD Stock Could Keep Climbing

Why AMD Stock Could Keep Climbing

AMD achieved its target price of $160 and now focuses on aggressive AI hardware expansion to challenge Nvidia's dominance. The Instinct MI300X GPUs, with up to 16,384 GPUs per supercluster, position AMD as a top contender for AI infrastructure. Q2 2024 saw 115% YoY revenue growth in AMD's data center segment, accounting for nearly half of the company's total revenue.

Seekingalpha | 2 years ago
AMD Up on Strong August Semiconductor Sales: Is the Stock a Buy?

AMD Up on Strong August Semiconductor Sales: Is the Stock a Buy?

AMD rides on upbeat industry sales data, strong portfolio, ZT and Silo acquisitions, and robust data center demand amid stiff competition from NVIDIA.

Zacks | 2 years ago
Why AI Chip Stocks Are the ‘Place to Be,' Says Analyst

Why AI Chip Stocks Are the ‘Place to Be,' Says Analyst

Artificial-intelligence-chip stocks had a rough third quarter, but the rest of the year looks brighter, Melius Research says.

Barrons | 2 years ago
AMD's stock has a big catalyst on the horizon. Can it live up to the hype?

AMD's stock has a big catalyst on the horizon. Can it live up to the hype?

Last year's Advancing AI event spurred a major rally in AMD shares. Here's what investors are looking for at this year's.

Marketwatch | 2 years ago
OpenAI o1 picks 2 stocks to buy after Q3 2024 earning season

OpenAI o1 picks 2 stocks to buy after Q3 2024 earning season

Most companies are gearing up to announce their Q3 2024 earnings reports, which are likely to influence investor interest in their respective stocks, with an artificial intelligence (AI) tool offering insights on entities likely to stand out.

Finbold | 2 years ago
AMD stock price could surge by 33%, but Oct. 29 will be crucial

AMD stock price could surge by 33%, but Oct. 29 will be crucial

The AMD (NASDAQ: AMD) stock price has crawled back in the past few weeks, rising from the August low of $121.80 to the current $170. It has jumped by over 208% from its lowest point in 2020.

Invezz | 2 years ago
What You Need To Know Ahead of AMD's Advancing AI Event

What You Need To Know Ahead of AMD's Advancing AI Event

Advanced Micro Devices (AMD) is gearing up to showcase new tech at its 2024 Advancing AI event on Thursday, which Bank of America analysts said could be a "catch-up catalyst" for the chipmaker.

Investopedia | 2 years ago
AMD Stock Rallies and Recent Updates

AMD Stock Rallies and Recent Updates

Advanced Micro Devices, Inc. (AMD, Financial)'s stock has surged by 22.61% year-to-date, despite facing short-term headwinds on its first semester's report. This uptrend is believed to continue.

Gurufocus | 2 years ago
Why Advanced Micro Devices Stock Gained 10% in September

Why Advanced Micro Devices Stock Gained 10% in September

Excitement is building for AMD's upcoming AI event.

Fool | 2 years ago
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

4D Molecular Therapeutics' lead candidate, 4D-150, aims to provide a one-time gene therapy for Wet-AMD, showing promising but mixed Phase 2 data. Despite setbacks, 4D-150's potential for less frequent dosing and robust safety profile make it an intriguing investment, especially given 4D's strong cash position. The competitive landscape is fierce, with rivals like AbbVie and Adverum, but 4D-150 could still achieve significant market share if approved.

Seekingalpha | 2 years ago
Loading...
Load More